Document Detail

Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
MedLine Citation:
PMID:  21554150     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: In the last couple of years, the number of patients with chronic inflammatory rheumatic diseases being treated with TNF α antagonist has increased dramatically. Adalimumab, a fully human monoclonal antibody against TNF α, is one of the most frequently administered TNF α antagonists. Yet, unresolved issues are the long-term safety of TNF α antagonists and high treatment costs.
AREAS COVERED: The authors summarize the available data on short- and long-term efficacy and safety of adalimumab in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. The reader will find a comprehensive overview on the safety and efficacy of adalimumab for these conditions. Clinically relevant questions of adalimumab therapy are discussed. A special focus of this review is on the safety of adalimumab therapy.
EXPERT OPINION: Adalimumab is effective and reasonably safe in the short- and long-term treatment of patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis who do not respond to the standard therapy. It inhibits radiographic progression in rheumatoid and psoriatic arthritis. Treatment with a TNF α inhibitor such as adalimumab is associated with high treatment costs.
Denis Poddubnyy; Martin Rudwaleit
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-10
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  10     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-06-13     Completed Date:  2012-05-07     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  655-73     Citation Subset:  IM    
Charite - Campus Benjamin Franklin, Department of Rheumatology , Hindenburgdamm 30, 12203 Berlin , Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal, Humanized / adverse effects,  metabolism,  therapeutic use*
Arthritis, Psoriatic / drug therapy*,  metabolism,  radiography
Arthritis, Rheumatoid / drug therapy*,  metabolism,  radiography
Clinical Trials as Topic / methods
Drug Toxicity / chemically induced,  metabolism
Spondylitis, Ankylosing / drug therapy*,  metabolism,  radiography
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors,  metabolism
Reg. No./Substance:
0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Challenges in assessing regional distribution of inhaled drug in the human lungs.
Next Document:  Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma.